SCHEMBL5745201

SCHEMBL5745201

OC1CCN(C(c2ccccc2)c2ccccc2)CC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL3 Q96JM7 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
OPRM1 P35372 7/20 0.57
OPRK1 P41145 5/20 0.57
OPRL1 P41146 5/20 0.57
ALDH1A1 P00352 1/20 0.56
KMT2A Q03164 4/20 0.55
MEN1 O00255 2/20 0.55
CHRM2 P08172 1/20 0.55
CHRM4 P08173 1/20 0.55
CHRM5 P08912 1/20 0.55
ADRA2A P08913 1/20 0.55
ADORA3 P0DMS8 1/20 0.55
CYP2D6 P10635 1/20 0.55
CHRM1 P11229 1/20 0.55
CHRM3 P20309 1/20 0.55
DRD1 P21728 1/20 0.55
ADRA1D P25100 1/20 0.55
HTR2A P28223 1/20 0.55
HTR2C P28335 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL10797918 0.98 L3MBTL3 (0.59) L3MBTL3L3MBTL1OPRM1OPRK1OPRL1
SCHEMBL2267354 0.89 L3MBTL3 (0.53) L3MBTL3L3MBTL1OPRM1OPRK1OPRL1
SCHEMBL2267306 0.89 L3MBTL3 (0.53) L3MBTL3L3MBTL1OPRM1OPRK1OPRL1
SCHEMBL5745487 0.88 CYP2D6 (0.51) L3MBTL3L3MBTL1OPRM1OPRK1OPRL1
SCHEMBL4261834 0.83 L3MBTL3 (0.55) L3MBTL3L3MBTL1OPRM1OPRK1OPRL1
SCHEMBL5743946 0.81 CYP2D6 (0.49) L3MBTL3L3MBTL1OPRM1OPRK1OPRL1
SCHEMBL19631653 0.81 KCNA3 (0.51) L3MBTL3L3MBTL1OPRM1OPRK1OPRL1
SCHEMBL7944686 0.81 ACHE (0.51) OPRM1OPRK1OPRL1OPRD1
SCHEMBL19614197 0.81 CYP2D6 (0.68) L3MBTL3OPRM1OPRK1OPRL1ALDH1A1
SCHEMBL19613224 0.81 CYP2D6 (0.68) L3MBTL3OPRM1OPRK1OPRL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250034120-A1 PYRIDAZINONES AS PARP7 INHIBITORS RIBON THERAPEUTICS, INC. 2025-01-30 US disclosed
EP-4234551-A2 PYRIDAZINONES AS PARP7 INHIBITORS Ribon Therapeutics Inc. (US) 2023-08-30 EP disclosed
US-20230192664-A1 PYRIDAZINONES AS PARP7 INHIBITORS ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE 2023-06-22 US disclosed
EP-3788040-B1 PYRIDAZINONES AS PARP7 INHIBITORS RIBON THERAPEUTICS INC (US) 2023-04-12 EP disclosed
US-11566020-B1 Pyridazinones as PARP7 inhibitors RIBON THERAPEUTICS, INC. (US) 2023-01-31 US disclosed
US-11014913-B2 Pyridazinones as PARP7 inhibitors RIBON THERAPEUTICS, INC. (US) 2021-05-25 US disclosed
EP-3788040-A1 PYRIDAZINONES AS PARP7 INHIBITORS Ribon Therapeutics Inc. (US) 2021-03-10 EP disclosed
CN-112424188-A Pyridazinones as PARP7 inhibitors 里邦医疗公司 2021-02-26 CN disclosed
US-20210024502-A1 PYRIDAZINONES AS PARP7 INHIBITORS ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE 2021-01-28 US disclosed
US-10870641-B2 Pyridazinones as PARP7 inhibitors RIBON THERAPEUTICS, INC. (US) 2020-12-22 US disclosed
US-6992205-B2 Process for the production of sulfonic esters KANEKA CORPORATION (JP) 2006-01-31 US disclosed
US-6864372-B2 Process for the production of sulfonic esters KANEKA CORPORATION (JP) 2005-03-08 US disclosed
US-6794519-B2 Process for the production of sulfonic esters KANEKA CORPORATION (JP) 2004-09-21 US disclosed
US-20030176713-A1 Reacting an amino alcohol derivative with organic sulfonyl halide in a mixed solvent composed of an aprotic organic solvent and water in presence of a non-water prohibiting inorganic base KANEKA CORPORATION (JP) 2003-09-18 US disclosed
US-20030176711-A1 Process for the production of sulfonic esters KANEKA CORPORATION (JP) 2003-09-18 US disclosed
US-20030162966-A1 PROCESS FOR THE PRODUCTION OF SULFONIC ESTERS KANEKA CORPORATION (JP) 2003-08-28 US disclosed
EP-1288198-A1 PROCESS FOR THE PRODUCTION OF SULFONIC ESTERS KANEKA CORPORATION (JP) 2003-03-05 EP disclosed
US-4642348-A ANTIARRHYTHMIA AGENTS A. H. ROBINS COMPANY, INCORPORATED (US) 1987-02-10 US disclosed
US-4593102-A N-[(amino)alkyl]-1-pyrrolidine, 1-piperidine and 1-homopiperidinecarboxamides (and thiocarboxamides) with sulfur linked substitution in the 2, 3 or 4-position A. H. ROBINS COMPANY, INC. (US) 1986-06-03 US disclosed
EP-0160436-A2 N-[(Amino)Alkyl]-1-pyrrolidine, 1-piperidine and 1-homopiperidinecarboxamides (and thiocarboxamides) with sulphur linked substitution in the 2, 3 or 4-position A.H. ROBINS COMPANY, INCORPORATED (US) 1985-11-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210024502-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 L3MBTL3 2634/4885L3MBTL1 2933/4885OPRM1 3715/4885
US-20030162966-A1 PROCESS FOR THE PRODUCTION OF SULFONIC ESTERS TST, STS, SELENOI L3MBTL3 3743/4885L3MBTL1 3101/4885OPRM1 2799/4885
US-20250034120-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 L3MBTL3 2634/4885L3MBTL1 2933/4885OPRM1 3715/4885
US-11014913-B2 Pyridazinones as PARP7 inhibitors PARP2, PARP1, PARP4 L3MBTL3 2634/4885L3MBTL1 2933/4885OPRM1 3715/4885
US-11566020-B1 Pyridazinones as PARP7 inhibitors PARP2, PARP1, PARP4 L3MBTL3 2634/4885L3MBTL1 2933/4885OPRM1 3715/4885
US-10870641-B2 Pyridazinones as PARP7 inhibitors PARP2, PARP1, PARP4 L3MBTL3 2634/4885L3MBTL1 2933/4885OPRM1 3715/4885
US-20030176711-A1 Process for the production of sulfonic esters TST, STS, SELENOI L3MBTL3 3743/4885L3MBTL1 3101/4885OPRM1 2799/4885
US-20230192664-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 L3MBTL3 2634/4885L3MBTL1 2933/4885OPRM1 3715/4885
US-20030176713-A1 Reacting an amino alcohol derivative with organic sulfonyl halide in a mixed solvent composed of an aprotic organic solvent and water in presence of a non-water prohibiting inorganic base BRAF, ADH1C, TST L3MBTL3 2560/4885L3MBTL1 2186/4885OPRM1 1372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.